Zydus Lifesciences wraps up enrollment for Phase II ALS trial of Usnoflast
Zydus Lifesciences, a renowned global pharmaceutical company, has achieved a significant milestone by completing the enrollment for the Phase II clinical trial of its novel ... Read More
Zydus Lifesciences announces WHO approval for NLRP3 inhibitor Usnoflast
Zydus Lifesciences, a discovery-based, global pharmaceutical leader, has recently received approval from the World Health Organization (WHO) International Non-proprietary Names (INN) for "Usnoflast" as the ... Read More